Muscle-Bone Crosstalk During Prolonged ICU Stay

Abstract

Muscle-bone crosstalk refers to the intricate bidirectional communication between skeletal muscle and bone tissue, which is disrupted during prolonged intensive care unit (ICU) stays. Critical illness-induced immobilization, systemic inflammation, and altered metabolic states profoundly affect both muscle and bone, leading to muscle wasting, bone demineralization, and functional decline. This review synthesizes recent evidence on the mechanisms, clinical features, diagnosis, and management of muscle-bone crosstalk disturbances in ICU patients, emphasizing the need for integrated care strategies and emerging therapeutic approaches.

Introduction

Prolonged ICU admission is increasingly recognized as a trigger for acute and chronic musculoskeletal complications, notably due to the breakdown in muscle-bone crosstalk. This phenomenon encompasses the molecular and cellular interactions that maintain musculoskeletal integrity, which are acutely compromised under conditions of critical illness. Disruption of these pathways contributes not only to physical impairment and delayed rehabilitation but also to an increased risk of fractures and long-term disability. As the population of ICU survivors grows, understanding muscle-bone crosstalk has become vital for optimizing outcomes and developing targeted interventions.

Epidemiology / Disease Burden

The prevalence of ICU-acquired weakness (ICUAW) ranges from 25% to 60% in patients with stays exceeding one week, with studies demonstrating concurrent bone loss in up to 50% of these individuals. The disease burden is substantial: muscle wasting and osteoporosis contribute to prolonged mechanical ventilation, increased length of stay, and higher rates of hospital readmission. Epidemiological data suggest that up to 30% of ICU survivors experience clinically significant bone loss within six months post-discharge, underscoring the importance of early recognition and management.

Pathophysiology

Muscle-bone crosstalk is mediated by mechanical loading, myokines (e.g., irisin, myostatin), and osteokines (e.g., osteocalcin, sclerostin). In the ICU, immobilization leads to reduced mechanical stimulation, diminishing muscle-derived anabolic signals and promoting catabolism. Systemic inflammation, mediated by cytokines such as TNF-α and IL-6, exacerbates muscle proteolysis and bone resorption. Hormonal imbalances, including decreased growth hormone, testosterone, and vitamin D, further impair musculoskeletal health. The resulting cycle of muscle atrophy and bone demineralization is self-perpetuating, with each tissue negatively influencing the other via paracrine and endocrine mechanisms.

Risk Factors

Key risk factors for disrupted muscle-bone crosstalk during ICU stay include advanced age, pre-existing frailty, prolonged immobilization, severe systemic inflammation (e.g., sepsis, ARDS), corticosteroid use, malnutrition, and comorbidities such as diabetes and chronic kidney disease. Iatrogenic factors, such as excessive sedation and neuromuscular blockade, also contribute by limiting early mobilization and exacerbating catabolic states.

Clinical Features

Clinically, patients present with profound muscle weakness, reduced functional capacity, and increased risk of falls and fractures. Objective findings include decreased muscle mass (assessed by ultrasound or CT), low bone mineral density (BMD) measured by DXA, and biochemical markers of increased bone turnover. These features often coexist with other complications of critical illness, such as neuropathy and impaired wound healing, complicating the clinical picture and management.

Diagnosis

Diagnosis of muscle-bone crosstalk disturbances is multifaceted. Muscle strength can be evaluated using the Medical Research Council (MRC) sum score or handgrip dynamometry. Imaging modalities such as DXA and quantitative CT provide assessment of bone health. Laboratory evaluation includes serum creatine kinase, C-terminal telopeptide, and bone-specific alkaline phosphatase. Early identification relies on a combination of clinical assessment, functional testing, and biochemical markers, ideally performed in a multidisciplinary context.

Treatment & Management

Management strategies are multidisciplinary, aiming to mitigate muscle and bone loss through early mobilization, nutritional optimization (adequate protein and calcium/vitamin D intake), minimization of iatrogenic factors, and pharmacologic interventions as appropriate. Physical therapy should commence as soon as clinically feasible, employing progressive resistance exercises tailored to patient capacity. Bisphosphonates or denosumab may be considered for patients at high risk of osteoporosis, although their use in the acute ICU setting remains under investigation. Correction of vitamin D deficiency and hormonal imbalances is recommended based on current guidelines.

Recent Advances / Emerging Therapies

Recent insights have highlighted the therapeutic potential of targeting myokine and osteokine pathways. Agents modulating myostatin signaling, such as follistatin analogues, are under evaluation for muscle preservation. Sclerostin inhibitors, originally developed for osteoporosis, may offer dual benefit by promoting bone formation and indirectly supporting muscle function. Non-pharmacological innovations, such as neuromuscular electrical stimulation and vibration therapy, have demonstrated promise in mitigating muscle and bone loss during immobilization. Ongoing research is exploring the integration of these modalities into standard ICU care protocols.

Guideline Recommendations

Recent guidelines from critical care and musculoskeletal societies emphasize early mobilization, frequent assessment of nutritional status, and minimization of corticosteroid exposure. The European Society of Intensive Care Medicine (ESICM) and other organizations recommend routine screening for ICUAW and bone health in high-risk populations, with multidisciplinary rehabilitation initiated within the first week of ICU admission when feasible. Pharmacologic interventions should be individualized, balancing benefits against potential adverse effects, and always in conjunction with non-pharmacologic strategies.

Conclusion

The disruption of muscle-bone crosstalk during prolonged ICU stay is a clinically significant phenomenon with profound implications for patient outcomes. Early recognition, comprehensive assessment, and integrated therapeutic interventions are essential for mitigating musculoskeletal complications and optimizing recovery. Continued research into mechanism-based therapies and multidisciplinary care models will be critical for improving the long-term musculoskeletal health of ICU survivors.